SCHEMBL12756643

SCHEMBL12756643

O=C(Nc1csc(-c2ccc(Cl)cc2)c1C(=O)O)OCc1ccccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.41
CYP1A2 P05177 3/20 0.40
CYP2D6 P10635 3/20 0.40
CYP2C19 P33261 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 3/20 0.40
CYP2C9 P11712 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ANO1 Q5XXA6 3/20 0.39
PRKCZ Q05513 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15479112 0.90 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL12756644 0.89 MEN1 (0.45) TDP1CYP1A2CYP2D6CYP2C19ALDH1A1
SCHEMBL1491014 0.86 HDAC3 (0.50) CYP1A2CYP2D6CYP2C19MEN1KMT2A
SCHEMBL12830004 0.83 ROCK2 (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL12830743 0.83 CNR1 (0.42) MEN1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL12756639 0.81 MEN1 (0.43) CYP1A2CYP2D6CYP2C19ALDH1A1MEN1
SCHEMBL12756898 0.79 MEN1 (0.53) TDP1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL1490651 0.77 NPC1 (0.48) CYP1A2CYP2D6CYP2C19MEN1KMT2A
SCHEMBL12756649 0.75 HCAR2 (0.43) MEN1KMT2ASMN1; SMN2CYP2C9ANO1
SCHEMBL12830152 0.75 TRPA1 (0.43) TDP1ALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 US disclosed
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 US disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 US disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 TDP1 3096/4885CYP1A2 4570/4885CYP2D6 4537/4885
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 TDP1 3096/4885CYP1A2 4570/4885CYP2D6 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.